CannTrust Holdings Inc (TSX: TRST)(NYSE: CTST) has named Dr Len Walt, MD, MBA as its new chief medical officer, it was reported yesterday.
Dr Walt will lead the global medical function dedicated to strengthening the company's clinical research strategy, medical education programs, product innovation and support the expansion of CannTrust's global medical businesses and partnerships.
Dr Walt comes to CannTrust with extensive senior leadership experience in the pharmaceutical and biotechnology industries in Canada, USA and abroad. Most recently he held the position of vice president and head of Medical Affairs at Sobi Inc, where he led the company's North American medical and scientific operations. Previously, he held the position of medical director at Biogen Canada, where he built medical teams and developed relationships with key clinical investigators in Canada.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA